Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

Université Laval

$860,626.00

The implication of PlGF in cutaneous fibrosis

FY 2021-22

Summary
There are many diseases that result in an increase in the amount of extracellular matrix, making the skin hard and inelastic. Among these diseases, scleroderma and hypertrophic scars are two disabling conditions that currently receive little effective treatment. We have determined that a molecule called PlGF stimulates the production of the extracellular matrix and is greatly increased in patients with this disease. Our study aims to understand the link between PlGF and fibrosis. We will use biopsies of pathological skins, cells cultured in 2D and 3D and an animal model of the pathology. This research will allow us to be the first to position PlGF as a potential therapeutic target in fibrotic diseases. The obtained results will validate in vitro findings, predict the impact in humans, and provide critical information on the modulation of fibrosis, which is essential to substantiate the use of the PlGF antibody as a promising therapeutic target.
Program
Project Grant
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
461612
Name
Moulin Véronique
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Clinical Investigation - B: Arthritis, Bone, Skin and Cartilage
Projecttitle
The implication of PlGF in cutaneous fibrosis
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$860,626
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Cytokine; Fibrosis; Hypertrophic Scar; Matrix; Plgf; Scleroderma; Skin
Abstract
There are many diseases that result in an increase in the amount of extracellular matrix, making the skin hard and inelastic. Among these diseases, scleroderma and hypertrophic scars are two disabling conditions that currently receive little effective treatment. We have determined that a molecule called PlGF stimulates the production of the extracellular matrix and is greatly increased in patients with this disease. Our study aims to understand the link between PlGF and fibrosis. We will use biopsies of pathological skins, cells cultured in 2D and 3D and an animal model of the pathology. This research will allow us to be the first to position PlGF as a potential therapeutic target in fibrotic diseases. The obtained results will validate in vitro findings, predict the impact in humans, and provide critical information on the modulation of fibrosis, which is essential to substantiate the use of the PlGF antibody as a promising therapeutic target.
Competitiondate
202203
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Moulin, Véronique
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $860,626~ $0~